Table 2.

Univariable and multivariable linear regression analyses of the relationship between LV trabeculation and clinical parameters

Variants	Univariable linear regression		Multivariable linear regression
	Unadjusted β value (95% CI)	Unadjusted P-value	Adjusted β value (95% CI)	Adjusted P-value
Age	− 0.002 (− 0.007–0.002)	0.324
Sex (female vs. male)	0.172 (0.031–0.313)	0.017	0.197 (0.053–0.340)	0.007
Syncope	− 0.002 (− 0.204–0.200)	0.984
NYHA greater than I	− 0.070 (− 0.212–0.072)	0.332
Atrial fibrillation	− 0.112 (− 0.287–0.063)	0.208
NSVT	− 0.169 (− 0.402–0.064)	0.155
Coronary artery disease	0.100 (− 0.123–0.323)	0.378
Valvular heart disease	0.069 (− 0.261–0.399)	0.682
Carotid artery disease	0.061(− 0.366–0.245)	0.697
Chronic kidney disease	0.048 (− 0.534–0.631)	0.871
Stroke history	0.079 (− 0.580–0.422)	0.757
Septal reduction therapy	− 0.004 (− 0.141–0.134)	0.958
Family history of SCD	0.246 (0.030–0.461)	0.025	0.172 (− 0.043–0.386)	0.117
LVWT	− 0.005 (− 0.017–0.007)	0.456
LVEDD	0.001 (−0.001–0.012)	0.920
LVEDVi	0.002 (− 0.001–0.005)	0.163
LVEF < 50%	0.891 (0.416–1.365)	< 0.001	0.515 (0.013–1.016)	0.044
LAD	− 0.002 (− 0.012–0.007)	0.630
LVOTG	− 0.002 (− 0.004 to − 4.210e-4)	0.014	− 0.002 (− 0.004 to − 1.600e-4)	0.032
LV apical aneurysm	0.150 (− 0.479–0.778)	0.640
Extensive LGE	0.434 (0.207–0.662)	< 0.001	0.327 (0.089–0.565)	0.007

HCM hypertrophic cardiomyopathy, LAD left atrial diameter, LGE late gadolinium enhancement, extensive LGE defined as LGE extent ≥ 15%, LV left ventricular, LVEDD, LV end-diastolic diameter, LVEDVi LV end-diastolic volume index, LVEF LV ejection fraction, LVOTG LV outflow tract (LVOT) gradient, LVWT maximal left ventricular (LV) wall thickness, NSVT non-sustained ventricular tachycardia, NYHA New York Heart Association, SCD sudden cardiac death